Welcome to our dedicated page for Mirum Pharmaceuticals SEC filings (Ticker: MIRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mirum Pharmaceuticals, Inc. filings document operating results, product-sales disclosures, clinical program updates and governance matters for a rare disease biopharmaceutical company. Its 8-K reports furnish earnings releases, preliminary sales information, Regulation FD investor materials and other event disclosures tied to LIVMARLI, CHOLBAM, CTEXLI and investigational programs such as volixibat and brelovitug.
The company’s SEC record also covers capital-structure and transaction disclosures, including the completed Bluejay Therapeutics acquisition, related pro forma financial information and a PIPE financing. Proxy filings describe annual meeting matters, board elections, executive compensation and equity-plan governance, while registration details identify Mirum common stock as listed on the Nasdaq Global Market under MIRM.
Mirum Pharmaceuticals, Inc. director and chief executive officer Christopher Peetz reported option exercises and share sales in the company’s stock. On June 1, 2026, he exercised stock options for 30,000 shares of common stock at an exercise price of $2.936 per share and sold 30,000 shares of common stock in multiple open-market transactions. The sales occurred at prices ranging from about $93.90 to $99.79 per share pursuant to a pre-arranged Rule 10b5-1 Plan adopted on March 2, 2026. Following these transactions, he holds 224,309 shares of common stock directly and 187,500 shares indirectly through The Peetz Family Trust, as well as 128,487 stock options outstanding.
Director Timothy P. Walbert of Mirum Pharmaceuticals, Inc. exercised previously granted restricted stock units that converted into 3,977 shares of common stock on May 29, 2026. These units represented a contingent right to receive one share of common stock for each unit.
After the transaction, Walbert directly holds 9,680 shares of common stock. The filing shows a routine compensation-related derivative exercise, with no open-market buying or selling and no remaining restricted stock units from this grant.
Mirum Pharmaceuticals director Lon Cardon exercised 3,977 restricted stock units into common stock. These units each converted into one share on May 29, 2026, increasing his directly held common stock to 9,680 shares. The filing shows an equity award vesting, with no open‑market buying or selling.
Mirum Pharmaceuticals director Saira Ramasastry reported an exercise-and-sale transaction involving 3,977 shares of common stock. On May 29, 2026, 3,977 restricted stock units were converted into 3,977 shares of common stock at a stated price of $0.0000 per share. On June 1, 2026, all 3,977 shares were sold in an open-market transaction at $100.0000 per share, leaving 0 shares of common stock reported as directly held after the sale. The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 18, 2025, indicating the timing was set in advance.
Mirum Pharmaceuticals director Laurent Fischer exercised restricted stock units into common shares. On May 29, 2026, 3,977 restricted stock units, each representing a right to receive one share of common stock, were converted into 3,977 shares of Mirum common stock. Following this derivative exercise, Fischer directly holds 10,727 shares of common stock. The restricted stock units represented a contingent right that vested on May 29, 2026.
Christopher Peetz submitted a Rule 144 notice concerning ordinary shares of the issuer. The filing reports a sale of 40,985 shares on 03/16/2026 for $3,769,714.23 and an intended transaction involving 30,000 shares via a stock option exercise on 06/01/2026 to be settled for cash.
MIRM-related Form 144 filed for proposed sale of Common Stock. The filing lists 3,977 shares of Common Stock described as restricted stock to be sold on 05/29/2026. The notice also documents three prior open-market sales by Saira Ramasastry of 2,000 shares each on 03/16/2026, 04/15/2026, and 05/15/2026 with proceeds of $181,520, $193,800, and $218,940, respectively.
Mirum Pharmaceuticals, Inc. director Saira Ramasastry reported an exercise-and-sell transaction in company stock. On May 15, 2026, she exercised stock options to acquire 2,000 shares of common stock at $23.51 per share, then sold 2,000 shares in an open-market transaction at $109.47 per share. The filing shows these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 18, 2025, indicating they were scheduled in advance. After these transactions, her reported direct common stock holdings were 0 shares, and the exercised option covering 2,000 shares is fully vested and fully exercised.
Mirum Pharmaceuticals issued $690.0 million of 0.00% Convertible Senior Notes due 2032 in a private 144A placement to qualified institutional buyers, including a $90.0 million overallotment option that was fully exercised. The company estimates net proceeds of approximately $671.6 million after discounts and expenses. The notes are senior unsecured, carry no regular interest, and mature on June 1, 2032, with multiple triggers that allow conversion into cash, stock, or a mix, at Mirum’s election. The initial conversion rate is 7.1971 shares per $1,000, implying a conversion price of about $138.94 per share, a 30% premium to the $106.88 stock price on May 12, 2026, and could rise to a maximum rate of 9.3562 shares upon certain events. Mirum plans to use about $475.0 million of proceeds plus 3,220,529 shares to exchange approximately $237.2 million principal of its 4.00% Convertible Senior Notes due 2029, with the balance earmarked for general corporate purposes, including potential acquisitions.
MIRM submitted Form 144 notices reporting sales of Common Stock. The filing lists a 2,000-share sale tied to a stock option exercise dated 05/15/2026. It also records two sales in the prior three months: 2,000 shares on 04/15/2026 for $193,800 and 2,000 shares on 03/16/2026 for $181,520.